Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.39 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | TACR3 | P29371 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15303281 | 0.88 | SLC6A4 (0.37) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL1281808 | 0.86 | SLC6A2 (0.41) | ERBB2EPHA2EPHB4PDE4BSLC6A4 | |
| SCHEMBL1280069 | 0.84 | ERBB2 (0.43) | ERBB2EPHA2EPHB4PDE4BSLC6A4 | |
| SCHEMBL1280414 | 0.84 | ERBB2 (0.43) | ERBB2EPHA2EPHB4PDE4BSLC6A4 | |
| SCHEMBL1279913 | 0.84 | ERBB2 (0.43) | ERBB2EPHA2EPHB4PDE4BSLC6A4 | |
| SCHEMBL1279577 | 0.84 | ERBB2 (0.43) | ERBB2EPHA2EPHB4PDE4BSLC6A4 | |
| SCHEMBL1281223 | 0.84 | ERBB2 (0.43) | ERBB2EPHA2EPHB4PDE4BSLC6A4 | |
| SCHEMBL1280565 | 0.83 | ERBB2 (0.42) | ERBB2EPHA2EPHB4PDE4BSLC6A4 | |
| SCHEMBL1281154 | 0.83 | ERBB2 (0.42) | ERBB2EPHA2EPHB4PDE4BSLC6A4 | |
| SCHEMBL1281170 | 0.83 | EPHA2 (0.45) | ERBB2EPHA2EPHB4PDE4BSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088748-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088748-A1 | HETEROCYCLIC COMPOUNDS | SLC6A2, MAOB, MAOA | ERBB2 2516/4885EPHA2 3808/4885EPHB4 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.